eligibility_summary
Eligible: women ≥18 with FRα+ (IHC ≥5%) advanced HGS/E ovarian, fallopian tube or primary peritoneal cancer, negative BAT, platinum‑free interval <6 mo, ≤4 prior lines, measurable disease with a biopsiable non‑target lesion, ECOG 0–1, >3‑mo life, adequate marrow/immune (CD4≥500, CD8≥150), renal, hepatic, not pregnant, contraception. Exclude: non‑epithelial tumors, obstruction/ascites, severe allergy/asthma/parasite/tryptase+, recent therapy/steroids/live vaccine, autoimmune/ILD, CV/QT issues/drugs, breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06547840 tests MOv18 IgE, an investigational IgE-class monoclonal antibody given IV in FRα-positive, platinum-resistant ovarian cancer. Mechanism: MOv18 IgE binds folate receptor‑alpha (FRα) on tumor cells and engages the IgE Fc pathway (FcεRI) to recruit/activate immune effector cells, inducing antibody‑dependent cell‑mediated cytotoxicity and phagocytosis (ADCC/ADCP) and degranulation to kill FRα+ cells. Cells/pathways targeted: FRα‑expressing epithelial ovarian cancer cells, FcεRI-bearing effector cells—primarily mast cells and basophils, with contributions from dendritic cells/monocytes/macrophages—and CD23 (FcεRII) on antigen‑presenting/B cells, activating IgE‑mediated anti‑tumor responses. Phase Ib dose escalation/expansion focuses on safety and activity.